SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : PFE (Pfizer) How high will it go?
PFE 25.89+0.4%12:11 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: JPM who wrote (804)3/30/1998 6:27:00 PM
From: Barron Von Hymen  Read Replies (1) of 9523
 
Although my math was off, I do believe the Motley Fools have been reading my posts.

Mar 30, 1998 (6:10 PM ET) - The Motley Fool Evening News

Pharmaceutical firm Pfizer Inc. (NYSE:PFE - news) continued to rise in heavy trading, gaining $1 15/16 to $97 11/16
following the Food and Drug Administration's approval on Friday of male impotence drug Viagra. The company has declined to
speculate on potential sales, but has said the drug will cost $7 a tablet wholesale. An estimated 30 million men in the U.S. are
affected by erectile dysfunction. Assuming a mere one-tenth of these men opt to use Viagra just once a week, that could mean
up to $1.1 billion a year for Pfizer -- no small amount for a company that last year reported sales of $12.5 billion. If a third of
those 30 million men decided to use Viagra once a week, Pfizer could rake in $3.64 billion per annum in the U.S. alone. Viagra
is expected to be available by prescription by mid-April. Pfizer has two other drugs to boost sales this year, as well. It started
selling Trovan, a new antibiotic, earlier this year, and it expects to begin selling Zeldox, a new drug for schizophrenia, later this
year.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext